The Votes Are In: Highly Descriptive Marks Are Difficult to Protect
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by:Sashank Krothapally and Jacob R. Rosenbaum
HERITAGE ALLIANCE V. AMERICAN POLICY ROUNDTABLE
Before Prost, Taranto, and Stark. Appeal from the Trademark Trial and Appeal Board.
Summary: Continuous-use evidence is not necessarily prima facie evidence of acquired distinctiveness for a highly descriptive mark.
Heritage offered voter guides under the names “iVoterGuide” and “iVoterGuide.com” since 2008. American Policy Roundtable (APR) filed for registration of the marks “iVoters” and “iVoters.com” in 2019. Heritage opposed APR’s registration on the grounds of likelihood of confusion with Heritage’s marks, for which Heritage claimed priority of use. The Board held that Heritage’s marks were not protectable because they were highly descriptive and had not acquired distinctiveness (secondary meaning). Heritage appealed.
The Federal Circuit affirmed. The Federal Circuit held that substantial evidence supported the conclusion that Heritage’s iVoterGuide marks directly and immediately convey the whole product and thus are highly descriptive. Further, the Board was within its discretion to not accept continuous-use evidence as prima facie evidence of acquired distinctiveness, “especially for a highly descriptive mark.” Additionally, the Board did not err in giving little weight to Heritage’s declarations, which were all essentially identical in form and were from Heritage’s volunteers. Thus, substantial evidence supported the Board’s decision that Heritage’s marks were highly descriptive and had not acquired secondary meaning.
Editor: Sean Murray
More insights
The Prosecution Data Most IP Attorneys Never Look At
Most prosecution strategy is set before anyone looks at who is actually examining the application. What is sitting there unused Every examiner has a history: allowance rate, average number of office actions, how often an interview changes the outcome. None…
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…